{"altmetric_id":17061071,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Exelixis"],"first_seen_on":"2017-03-06T20:57:20+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1488832200,"links":["https:\/\/clinicaltrials.gov\/show\/NCT00940225"],"nct_id":"NCT00940225","pubdate":"2009-07-12T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Study of Cabozantinib (XL184) in Adults With Advanced Malignancies","type":"clinical_trial_study_record"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":8317445,"mean":7.0084957256017,"rank":1212704,"this_scored_higher_than_pct":84,"this_scored_higher_than":7029667,"rank_type":"exact","sample_size":8317445,"percentile":84},"similar_age_3m":{"total_number_of_other_articles":241882,"mean":13.682357762701,"rank":54697,"this_scored_higher_than_pct":76,"this_scored_higher_than":184374,"rank_type":"exact","sample_size":241882,"percentile":76},"this_journal":{"total_number_of_other_articles":24290,"mean":10.430791798757,"rank":4041,"this_scored_higher_than_pct":75,"this_scored_higher_than":18339,"rank_type":"exact","sample_size":24290,"percentile":75},"similar_age_this_journal_3m":{"total_number_of_other_articles":762,"mean":13.045195795007,"rank":81,"this_scored_higher_than_pct":85,"this_scored_higher_than":648,"rank_type":"exact","sample_size":762,"percentile":85}}},"demographics":[],"counts":{"total":{"posts_count":2},"news":{"unique_users_count":1,"unique_users":["oncology_nurse_advisor"],"posts_count":2}},"posts":{"news":[{"title":"Cabozantinib Active in Hepatocellular Carcinoma","url":"http:\/\/www.oncologynurseadvisor.com\/cabozantinib-clinically-active-in-advanced-recurrent-or-metastatic-hcc\/article\/642306\/","license":"public","citation_ids":[17061071],"posted_on":"2017-03-06T20:30:00+00:00","summary":"March 06, 2017 In a phase 2 trial, cabozantinib was clinically active in patients with advanced hepatocellular carcinoma.","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}},{"title":"Cabozantinib Active in Hepatocellular Carcinoma","url":"http:\/\/ct.moreover.com\/?a=29807684918&p=1pl&v=1&x=y4weonpXG1_Bnr4BDAV_cA","license":"public","citation_ids":[17061071],"posted_on":"2017-03-06T20:30:00+00:00","summary":"March 06, 2017 In a phase 2 trial, cabozantinib was clinically active in patients with advanced hepatocellular carcinoma.","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}}]}}